Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bulgarian PM reveals price for EU's new vaccine contract with Pfizer

04/12/2021 | 09:02am EDT

SOFIA/BRUSSELS, April 12 (Reuters) - Bulgarian Prime Minister Boyko Borissov has revealed that a big new vaccine supply contract that the European Union is seeking from Pfizer-BioNTech from 2022 will be at a significantly increased price.

The bloc is seeking the new supply deal with the two companies for up to 1.8 billion vaccines, of which is 900 million optional, to be delivered in 2022 and 2023, Reuters reported on Friday.

Borissov, speaking on Sunday, said the EU was negotiating the new contract at a price of 19.5 euros ($23.22) per dose.

"The prices are going up quickly," Borissov said during a trip to a village in southern Bulgaria.

"Pfizer's (price) was 12 euros, then increased to 15.5 euros. Now for 2022 and 2023 the European Union contracts are being signed for 900 million vaccines, but already at a price of 19.5 euros," he said.

That is a significant increase from 15.5 euros per dose the EU has paid for the 600 million Pfizer shots it has so far contracted, according to an EU internal document and officials.

An EU official involved in talks with vaccine makers confirmed the price cited by Borissov for the new contract but said negotiations had not been wrapped up yet.

The new contract would cover variants, meaning that the companies would offer enhanced shots if mutations of the coronavirus became prevalent, a second EU official said.

Borissov said: "Roughly this will cost 18 billion euros, at least ... That means that in the new budgets financial experts should earmark bigger, much bigger buffers for vaccines."

Borissov's government was among EU states who initially declined to buy their full share of Pfizer shots secured by the EU because they considered the vaccine too expensive, several EU officials have said.

The Balkan country of 7 million people, which has initially bet mainly on the AstraZeneca vaccine, has suffered from delays and decreased deliveries of its vaccines to the EU.

At present, Sofia has vaccinated some 7.7% of its population with a first dose, the slowest rate in the EU.

Borissov said his centre-right government has secured the deliveries of some 2.7 million Pfizer doses until the middle of June that should speed up rollout and ensure herd immunity for Bulgarians.

($1 = 0.8403 euros) (Reporting by Tsvetelia Tsolova in Sofia and Francesco Guarascio in Brussels; Editing by Jane Merriman)

© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.72% 7735 Delayed Quote.5.61%
BIONTECH SE 9.35% 183.71 Delayed Quote.125.36%
PFIZER, INC. 1.00% 39.58 Delayed Quote.6.47%
All news about ASTRAZENECA PLC
05:40pCorrection to Impact of U.S. Support for Patent Waiver on Vaccine Makers Arti..
04:54pASTRAZENECA PHARMA INDIA  : Key EU countries rebuff Biden on sharing COVID vacci..
04:16pAstraZeneca Weighs Seeking Full U.S. Approval for Covid Shot, Skipping Emerge..
04:04pAstraZeneca Weighs Seeking Full U.S. Approval for Covid Shot, Skipping Emerge..
03:48pMARKET CHATTER : WHO's Director General Calls for Countries to Support Waiving C..
01:19pU.S. Support for Patent Waiver Unlikely to Cost Covid-19 Vaccine Makers in Sh..
01:18pHow the U.S. locked up vaccine materials other nations urgently need
12:54pWHO Endorses China's Covid-19 Vaccine Sinopharm -- 4th Update
12:26pASTRAZENECA  : WHO panel OKs emergency use of China's Sinopharm vaccine
11:51aSINOVAC BIOTECH  : WHO gives emergency approval to first Chinese COVID-19 vaccin..
More news
Financials (USD)
Sales 2021 30 843 M - -
Net income 2021 4 575 M - -
Net Debt 2021 11 038 M - -
P/E ratio 2021 29,9x
Yield 2021 2,64%
Capitalization 142 B 142 B -
EV / Sales 2021 4,96x
EV / Sales 2022 4,35x
Nbr of Employees 76 100
Free-Float 95,8%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 27
Average target price 130,07 $
Last Close Price 108,20 $
Spread / Highest target 53,4%
Spread / Average Target 20,2%
Spread / Lowest Target -12,1%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON7.07%441 726
ROCHE HOLDING AG-3.06%284 771
PFIZER, INC.6.47%218 608
ABBVIE INC.8.03%204 861
MERCK & CO., INC.-4.14%196 943